United Kingdom

People: ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

24 May 2019
Change (% chg)

$-0.02 (-14.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Brancaccio, John 

Mr. John P. Brancaccio CPA is Independent Director of the Company. Mr. Brancaccio has been served as director of Synergy Pharmaceuticals, Inc. since July 2008. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from 2004 until 2017. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) as well as a director of Trovagene, Inc. and Rasna Therapeutics, Inc., a biotechnology company. Mr. Brancaccio’s chief financial officer experience provides him with valuable financial and accounting expertise which the Board believes qualifies him to serve as a director of our Company.

Basic Compensation

Total Annual Compensation, USD 59,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 44,211
Fiscal Year Total, USD 103,211

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --